MINERVA IMAGING ApS
Core data
Name | MINERVA IMAGING ApS |
Address | Lyshøjvej 21, 3650, Ølstykke |
Founded | Dec 8, 2011 |
| 215 / 186 | |
Locations (P-units) | 1View locations |
Website | https://www.minervaimaging.com/ |
 LinkedIn | minerva-imaging |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | MINERVA IMAGING ApS |
Address | Lyshøjvej 21, 3650, Ølstykke |
Founded | Dec 8, 2011 |
| 215 / 186 |
Locations (P-units) | 1View locations |
Website | https://www.minervaimaging.com/ |
| LinkedIn | minerva-imaging |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of MINERVA IMAGING ApS
Description
Minerva Imaging is an integrated CRO and CDMO specialized in targeted radionuclide therapies, advanced oncology and cardiovascular disease models, and in vivo molecular imaging for translational research and drug development. Its facility in Denmark provides integrated radiopharmaceutical research, drug development, and manufacturing services.
Minerva Imaging provides pre-clinical oncology studies, targeted radionuclide therapy studies, CMC and CDMO services, cardiovascular disease research, molecular imaging, and in vitro and ex vivo assays for radiopharmaceutical therapy development.
Company's own description on virk.dk
Description of key activities of the companyMinerva Imaging’s vision is to become the leading contract research and contract development organization for targeted radionuclide therapy, enabling improved treatment regimens for cancer patients with a focus on the use of advanced animal models within oncology and cardiovascular diseases and in vivo molecular imaging for translational research and drug development. We aim to excel in delivering customized cancer radiopharmaceutical research and serve as an extended research team to our collaborators. We have built a global leading R&D platform for targeted radionuclide therapy and Contract Development and Manufacturing (CDMO) to enable integrated planning and faster execution of promising new radionuclide theragnostic projects in close collaboration with leading researchers, biotech, and pharmaceutical companies. Minerva is at the forefront of R&D in the theragnostic area. We are in a very fast-paced environment, where our researchers directly impact the advancement of new improved, and lifesaving drugs for seriously ill cancer patients. We have the ambition to make a difference for our clients, collaborating on advancing new treatment modalities for patients.
Products & services
Pre-clinical oncology studies · Targeted radionuclide therapy studies · CMC services · CDMO services · Cardiovascular disease studies · In vivo molecular imaging · In vitro cell culture and co-culture · Primary cell isolation · External radiation treatment · Gene and miRNA expression analysis · Protein and cytokine expression and secretion analysis · Binding interaction assays · Mechanism-of-action studies · Phenotypic screening · Ex vivo radioactive tissue handling · Tissue extraction and preservation · DNA, RNA and protein isolation · Cellular phenotyping · Flow cytometry · Histology · Immunohistochemistry
Industries
Contract research organization (CRO) · Contract development and manufacturing organization (CDMO) · Radiopharmaceutical research and manufacturing · Translational cancer research · Drug development
Customer types
Clients developing drugs and radiopharmaceutical therapies · Research clients
Financials
| Reporting period | 2025DKK | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross profit | 162,133,000 | ||||||||
| Operating profit | 18,441,000 | ||||||||
| Profit before tax | 13,379,000 | ||||||||
| Net income | 9,611,000 | ||||||||
| Total assets | 313,221,000 | ||||||||
| Equity | 116,580,000 | ||||||||
| Avg. employees | 170 | ||||||||
2017–2025 Unlock financial history | |||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
From minervaimaging.com
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
Founders
| Founder | Registered as founder | Current roles | Ownership |
|---|---|---|---|
| Andreas Kjær | Registered as founderDec 8, 2011 | Current roles Board | Ownership 0 %Indirect via Curixus Family Holding ApS → McQueen TopCo ApS → McQueen MidCo ApS → McQueen FinCo ApS → McQueen BidCo ApS |
| Carsten Haagen Nielsen | Registered as founderDec 8, 2011 | Current roles BoardManagement | Ownership 0 %Indirect via Curixus Family Holding ApS → McQueen TopCo ApS → McQueen MidCo ApS → McQueen FinCo ApS → McQueen BidCo ApS |
People
| Person | Roles | Titles |
|---|---|---|
| Andreas Kjær | Roles Board | TitlesBESTYRELSESMEDLEM |
| Carsten Haagen Nielsen | Roles BoardManagement | TitlesBESTYRELSESMEDLEM • ADM. DIR. |
| Patrik Olof Dahlén | Roles Board | TitlesFORMAND |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| BUUS JENSEN, Statsautoriserede revisorer | AuditorMichael Markussen | RoleStatsautoriseret revisor | FromJul 3, 2026 |
| BUUS JENSEN, Statsautoriserede revisorer | AuditorMichael Markussen | RoleStatsautoriseret revisor | FromJul 3, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership100 % | Voting rights100 % | FromAug 22, 2025 |
Child companies
| Company | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership100 % | Voting rights100 % | FromNov 1, 2019 | |
| Ownership100 % | Voting rights100 % | FromDec 20, 2012 | |
| Ownership100 % | Voting rights100 % | FromAug 1, 2024 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇱🇺Cidron Mermaid 2 SARL | Ownership through | 45–66.66 % |
| Amalie Christine Lebech Kjær | 5.99–12.5 % | |
| Anna Sophie Lebech Kjær | 5.99–12.5 % | |
| August Aarup Nielsen | 4.49–10 % | |
| Freja Aarup Nielsen | 4.49–10 % | |
| Johan Aarup Nielsen | 4.49–10 % | |
| Andreas Kjær | 0 % | |
| Carsten Haagen Nielsen | 0 % |